Secondary central nervous system lymphoma: risk factors and prophylaxis.
Patients diagnosed with diffuse large-cell lymphoma, peripheral T-cell non-Hodgkin's lymphoma or mantle cell lymphoma (either with a high serum lactate dehydrogenase level), more than one extranodal site, or who are a high risk according to the international Prognostic Index, should receive central nervous system prophylaxis either with intrathecal or high-dose systemic chemotherapy. The appropriateness of the same prophylaxis at relapse needs to be addressed in further studies.
Montoto
Silvia
S
Medical Oncology Department, St. Bartholomew's Hospital, Little Britain 45, London EC1A 7BE, UK. silviamontoto@cancer.org.uk
Lister
T Andrew
TA
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000517:prevention & control* / Q000556:secondary; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*
D000903:Antibiotics, Antineoplastic